Global Idiopathic Pulmonary Fibrosis 2016-2020

  • ID: 3721855
  • Drug Pipelines
  • Region: Global
  • 60 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Afferent Pharmaceuticals
  • Biogen
  • Cipla
  • Gilead Sciences
  • Horizon Pharma
  • Novartis
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.

The analysts forecast the global idiopathic pulmonary fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Idiopathic Pulmonary Fibrosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Baxter International
- Boehringer Ingelheim
- F.Hoffmann-La Roche
- Prometheus Laboratories

Other prominent vendors
- Afferent Pharmaceuticals
- Amgen
- Biogen
- Bristol-Myers Squibb
- Cipla
- FibroGen
- Gilead Sciences
- GlaxoSmithKline
- GNI Group
- Horizon Pharma
- ImmuneWorks
- MediciNova
- MedImmune (subsidiary of AstraZeneca)
- Novartis
- Pfizer
- Promedior
- ProMetic Life Sciences
- Sanofi
- Shionogi
- Zai Lab

Market drivers
- Unmet medical need
- For a full, detailed list, view the full report

Market challenges
- Lack of proper diagnosis
- For a full, detailed list, view the full report

Market trends
- Patient assistance programs
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Afferent Pharmaceuticals
  • Biogen
  • Cipla
  • Gilead Sciences
  • Horizon Pharma
  • Novartis
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Disease overview
  • Understanding the disease
  • Pathogenesis
  • Signs and symptoms
  • Diagnosis
  • Management
  • Epidemiology
PART 06: Pipeline analysis
  • Lebrikizumab
  • Tipelukast
  • Tralokinumab
  • FG-3019
  • Simtuzumab
  • BMS-986020
  • AF-219
  • SAR156597
  • BG00011
  • PRM-151
  • PBI-4050
PART 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 08: Market segmentation by ROA
  • Oral
  • Parenteral
PART 09: Market segmentation by drug class
  • Systemic corticosteroids
  • Immunosuppressants
  • Tyrosine kinase inhibitors
  • Anti-fibrotic agents
PART 10: Geographical segmentation
  • Global idiopathic pulmonary fibrosis market by geographical segmentation 2015-2020
  • Idiopathic pulmonary fibrosis market in Americas
  • Idiopathic pulmonary fibrosis market in EMEA
  • Idiopathic pulmonary fibrosis market in APAC
PART 11: Market drivers
  • Special regulatory designations for pipeline candidates
  • Growth in patient population
  • Unmet medical needs
PART 12: Impact of drivers

PART 13: Market challenges
  • Unknown disease etiology
  • Lack of proper diagnosis
  • Increased use of off-label and alternative therapies
PART 14: Impact of drivers and challenges

PART 15: Market trends
  • Patient assistance programs
  • Increase in M&A
  • Rise in public awareness
PART 16: Vendor landscape
  • Competitive scenario
  • Market share analysis 2015
  • Baxter International
  • Boehringer Ingelheim
  • F Hoffmann-La Roche
  • Prometheus Laboratories
  • Other prominent vendors
PART 17: Appendix
  • List of abbreviations
PART 18: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Common symptoms of idiopathic pulmonary fibrosis
Exhibit 03: Other signs and symptoms of idiopathic pulmonary fibrosis
Exhibit 04: Treatment options for idiopathic pulmonary fibrosis
Exhibit 05: Drugs used in the treatment of idiopathic pulmonary fibrosis
Exhibit 06: Global idiopathic pulmonary fibrosis market: Pipeline portfolio
Exhibit 07: Global idiopathic pulmonary fibrosis market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global idiopathic pulmonary fibrosis drugs market by ROA
Exhibit 10: Global idiopathic pulmonary fibrosis drugs market segment by drug class
Exhibit 11: Global idiopathic pulmonary fibrosis market segmentation by geography 2015
Exhibit 12: Idiopathic pulmonary fibrosis market revenue by geography 2015-2020 ($ millions)
Exhibit 13: Idiopathic pulmonary fibrosis market in Americas 2015-2020 ($ millions)
Exhibit 14: Idiopathic pulmonary fibrosis market in EMEA 2015-2020 ($ millions)
Exhibit 15: Idiopathic pulmonary fibrosis market in APAC 2015-2020 ($ millions)
Exhibit 16: Key drivers
Exhibit 17: Impact of drivers
Exhibit 18: Key challenges
Exhibit 19: Impact of drivers and challenges
Exhibit 20: Key trends
Exhibit 21: Baxter International: Business segmentation by revenue 2014
Exhibit 22: Baxter International: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: Baxter International: Geographical segmentation by revenue 2014
Exhibit 24: Baxter International: Key takeaways
Exhibit 25: Boehringer Ingelheim: Business segmentation by revenue 2014
Exhibit 26: Boehringer Ingelheim: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 27: Boehringer Ingelheim: Geographical segmentation by revenue 2014
Exhibit 28: Boehringer Ingelheim: Key takeaways
Exhibit 29: F Hoffmann-La Roche: Business segmentation 2014 by revenue
Exhibit 30: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 31: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 32: F Hoffmann-La Roche: YoY growth and revenue generated from CellCept 2011-2014 ($ millions)
Exhibit 33: F.Hoffmann-La Roche: Key takeaways
Exhibit 34: Prometheus Laboratories: Product categories
Exhibit 35: Prometheus Laboratories: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Afferent Pharmaceuticals
  • Biogen
  • Cipla
  • Gilead Sciences
  • Horizon Pharma
  • Novartis
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: – Global Idiopathic Pulmonary Fibrosis Market 2016-2020

The author of the report recognizes the following companies as the key players in the Global Idiopathic Pulmonary Fibrosis Market: Baxter International, Boehringer Ingelheim, F.Hoffmann-La Roche, and Prometheus Laboratories.

Other Prominent Vendors in the market are: Afferent Pharmaceuticals, Amgen, Biogen, Bristol-Myers Squibb, Cipla, FibroGen, Gilead Sciences, GlaxoSmithKline, GNI Group, Horizon Pharma, ImmuneWorks, MediciNova, MedImmune (subsidiary of AstraZeneca), Novartis, Pfizer, Promedior, ProMetic Life Sciences, Sanofi, Shionogi, and Zai Lab.

Commenting on the report, an analyst from the research team said: “An emerging market trend is the rise in patient assistance programs. Vendors in the market provide co-pay assistance to people who purchase the indicated medications for idiopathic pulmonary fibrosis. For instance, Roche has a co-pay assistance program to provide financial assistance to patients who purchase Esbriet. According to the Esbriet Co-pay Card Program, an eligible patient receives a 12-month prescription free of cost, attaining a maximum benefit of $24,000 during this period. The company also provides Esbriet Access Solutions that provide co-pay cards, assistance in getting drugs, and provide healthcare coverage to patients.”

According to the report, a possible growth driver is the unmet medical needs of many patients. Due to the unknown disease etiology, there is no specific cure for idiopathic pulmonary fibrosis. Therapies that target the exact cause of the disease cannot be developed owing to the idiopathic nature of the disease. Even the drugs marketed for the symptomatic treatment of the disease present different effects such as upper respiratory tract infections, liver problems, nausea and vomiting, diarrhea, headache, heartburn, weight loss, and high blood pressure. This results in decreased patient compliance, creating an unmet need in the market. Pharmaceutical companies and researchers are interested in developing a drug that provides a complete cure for the disease, with minimal side effects.

Further, the report states that one challenge that could market growth is the lack of proper diagnosis of this condition.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

- Baxter International
- Boehringer Ingelheim
- F.Hoffmann-La Roche
- Prometheus Laboratories
- Afferent Pharmaceuticals
- Amgen
- Biogen
- Bristol-Myers Squibb
- Cipla
- FibroGen
- Gilead Sciences
- GlaxoSmithKline
- GNI Group
- Horizon Pharma
- ImmuneWorks
- MediciNova
- MedImmune (subsidiary of AstraZeneca)
- Novartis
- Pfizer
- Promedior
- ProMetic Life Sciences
- Sanofi
- Shionogi
- Zai Lab.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll